cefozopran

Cefozopran is a semisynthetic, broad-spectrum, fourth-generation cephalosporin antibiotic developed by Takeda. It is primarily used for the treatment of severe infections caused by both Gram-positive and Gram-negative bacteria, including those resistant to other antibiotics such as *Staphylococcus aureus*, *Enterococcus faecalis*, *Pseudomonas aeruginosa*, and *Citrobacter freundii*. Cefozopran acts by binding to and inactivating **Penicillin-binding protein (PBP)** on the inner membrane of bacterial cell walls. This inhibits the final phase of peptidoglycan synthesis required for cell wall integrity, leading to bacterial cell lysis and death. The drug is resistant to hydrolysis by most chromosomal and plasmid-mediated β-lactamases. It has been marketed in Japan since the late 1990s for indications such as pneumonia, sepsis, urinary tract infections, intra-abdominal infections, obstetrical/gynecological infections, soft tissue infections, surgical site infections, bacterial meningitis (including pediatric use), and other severe or hospital-acquired infections[1][3][4][5][7][8].

Brand names

Firstcin

Other names

cefozopran hydrochloridecefozopran HClHCL, Cefozopran